Recipient outcomes. Recipients were transplanted with grafts mobilized with either SC (0.24 mg/kg; n = 38) or IV (0.32 mg/kg; n = 33) plerixafor. The time to neutrophil and platelet engraftment was defined as the first of 2 consecutive days with an absolute neutrophil count ≥0.5 × 109/L or a platelet count ≥50 × 109/L. (A) Cumulative incidence of neutrophil engraftment. (B) Cumulative incidence of platelet engraftment. (C) Cumulative incidence of aGVHD and (D) cGVHD in phase 2 recipients. (E) Incidence of grade 2-4 aGVHD in recipients of IV and SC plerixafor grafts. (F) Grade 3-4 aGVHD (G) and cGVHD in recipients surviving to 100 days. (H) Overall survival of recipients receiving plerixafor-mobilized allografts comparing IV with SC products. (I) Relapse-free survival of recipients receiving IV plerixafor grafts. Log-rank test was used to compare groups. Statistical comparisons of SC and IV plerixafor was performed by the log-rank (Mantel-Cox) test.
